Characterisation of the immune response to type I collagen in scleroderma
暂无分享,去创建一个
L. Carbone | A. Kang | Laura D Carbone | A. Postlethwaite | Kenneth J Warrington | Usha Nair | Andrew H Kang | Arnold E Postlethwaite | K. Warrington | U. Nair
[1] C. Weyand,et al. CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. , 1996, The Journal of clinical investigation.
[2] L. Fabbri,et al. Antibodies to the IL-12 receptor beta 2 chain mark human Th1 but not Th2 cells in vitro and in vivo. , 1999, Journal of immunology.
[3] B. Osterud,et al. Evidence for exclusive role of the p55 tumor necrosis factor (TNF) receptor in mediating the TNF-induced collagenase expression by human dermal fibroblasts. , 1996, The Journal of investigative dermatology.
[4] F. Arnett,et al. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. , 1999, Journal of immunology.
[5] H. Taskov,et al. Humoral and cellular immune response to elastin in patients with systemic sclerosis. , 1997, Autoimmunity.
[6] S. Jimenez,et al. Oligoclonal T Cell Expansion in the Skin of Patients with Systemic Sclerosis1 , 2002, The Journal of Immunology.
[7] B. Corrin,et al. Fibrosing alveolitis in systemic sclerosis: increase in memory T-cells in lung interstitium. , 1995, The European respiratory journal.
[8] S. Pahwa,et al. Augmented interleukin-6 secretion in collagen-stimulated peripheral blood mononuclear cells from patients with systemic sclerosis. , 1994, Annals of allergy.
[9] James F. Fries,et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.
[10] E. Leroy,et al. Cellular immunity to collagen and laminin in scleroderma. , 1985, Arthritis and rheumatism.
[11] M. Hasegawa,et al. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. , 2001, Journal of dermatological science.
[12] B. Berman,et al. Gamma interferon is the lymphokine and beta interferon the monokine responsible for inhibition of fibroblast collagen production and late but not early fibroblast proliferation , 1985, The Journal of experimental medicine.
[13] S. Jimenez,et al. Phenotype of peripheral blood lymphocytes in patients with progressive systemic sclerosis: activated T lymphocytes and the effect of D-penicillamine therapy. , 1987, Clinical and experimental immunology.
[14] S. Atamas,et al. Interleukin 4 in Systemic Sclerosis: Not Just an Increase , 1999, Clinical Diagnostic Laboratory Immunology.
[15] P. Ward,et al. Cellular sensitivity to collagen in bleomycin-treated rats. , 1982, Journal of immunology.
[16] H. McFarland,et al. CD4+CD28- costimulation-independent T cells in multiple sclerosis. , 2001, The Journal of clinical investigation.
[17] L. Chess,et al. Expression of the α1β1 integrin, VLA-1, marks a distinct subset of human CD4+ memory T cells , 2003 .
[18] R. Crystal,et al. Pathogenic mechanisms in pulmonary fibrosis: collagen-induced migration inhibition factor production and cytotoxicity mediated by lymphocytes. , 1976, The Journal of clinical investigation.
[19] M. Feldmann,et al. The method of deriving human T‐cell clones alters the proportion of IL‐10‐producing cells , 1996, Immunology.
[20] M. Liang,et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.
[21] M. Jinnin,et al. Antagonistic Effects of TNF-α on TGF-β Signaling Through Down-Regulation of TGF-β Receptor Type II in Human Dermal Fibroblasts1 , 2003, The Journal of Immunology.
[22] A. Vallejo,et al. Modulation of CD28 expression: distinct regulatory pathways during activation and replicative senescence. , 1999, Journal of immunology.
[23] C. Platsoucas,et al. Is systemic sclerosis an antigen-driven T cell disease? , 2004, Arthritis and rheumatism.
[24] J. R. Reeves,et al. Cellular infiltrates in scleroderma skin. , 1977, Arthritis and rheumatism.
[25] Zhaohui Qian,et al. Ex Vivo Characterization of the Autoimmune T Cell Response in the HLA-DR1 Mouse Model of Collagen-Induced Arthritis Reveals Long-Term Activation of Type II Collagen-Specific Cells and Their Presence in Arthritic Joints1 , 2005, The Journal of Immunology.
[26] J. Seyer,et al. Investigation of type I and type III collagens of the lung in progressive systemic sclerosis. , 1981, Arthritis and rheumatism.
[27] H. Katai,et al. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. , 1992, The Journal of clinical investigation.
[28] B. White,et al. Immunopathogenesis of systemic sclerosis. , 1996, Rheumatic diseases clinics of North America.
[29] T. Whiteside,et al. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. , 1984, Arthritis and rheumatism.
[30] J. Seyer,et al. Collagen polymorphism in normal and cirrhotic human liver. , 1977, The Journal of clinical investigation.
[31] M. Fujimoto,et al. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. , 1997, The Journal of rheumatology.
[32] S. Maleki,et al. Characterization of lymphocyte responses to peanuts in normal children, peanut-allergic children, and allergic children who acquired tolerance to peanuts. , 2003, The Journal of clinical investigation.
[33] A. B. Lyons,et al. Determination of lymphocyte division by flow cytometry. , 1994, Journal of immunological methods.
[34] G. Delespesse,et al. Human naive CD4 T cells produce interleukin‐4 at priming and acquire a Th2 phenotype upon repetitive stimulations in neutral conditions , 1995, European journal of immunology.
[35] A. Kang,et al. Evidence for cell-mediated immunity to collagen in progressive systemic sclerosis. , 1976, The Journal of laboratory and clinical medicine.
[36] R. Wise,et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. , 1999, Arthritis and rheumatism.
[37] A. Masi. Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.
[38] C. Mele,et al. Increased interleukin-2 production in response to human type I collagen stimulation in patients with systemic sclerosis. , 1991, Arthritis and rheumatism.
[39] A. Freemont,et al. Sequential dermal microvascular and perivascular changes in the development of scleroderma , 1992, The Journal of pathology.
[40] A. Reddi,et al. Extracellular matrix biochemistry , 1984 .
[41] S. Todesco,et al. Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity. , 1993, Annals of the rheumatic diseases.
[42] R. Scorza,et al. Increased interferon‐gamma (IFN‐γ) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud's phenomenon , 1999, Clinical and experimental immunology.
[43] J. Hales,et al. Potent Costimulation of Effector T Lymphocytes by Human Collagen Type I1 , 2000, The Journal of Immunology.
[44] L. Carbone,et al. Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. , 2000, Arthritis and rheumatism.
[45] T. Medsger,et al. Soluble serum interleukin 2 receptors in patients with systemic sclerosis. , 1996, The Journal of rheumatology.